drugset
Drugs / Mesenchymal Stem Cell-Derived Exosomes
last change Sep 2026 re-read 3 minutes ago

Mesenchymal Stem Cell-Derived Exosomes

Other / unclassified

Developed for
endotheliitis · mucositis · preeclampsia · puerperal disorder
Investigated by
Dr Cipto Mangunkusumo General Hospital · Dr. Hasan Sadikin General Hospital, Bandung, Indonesia · Dr. Sardjito Hospital, Yogyakarta · First Affiliated Hospital of Guangxi Medical University · First People's Hospital of Yulin · LiuZhou People's Hospital
+1 more · Padjadjaran University

Trials 2

today NCT07312656 · Ph 2 NCT07183384 · Ph 1/2
202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/21 trial
Phase 1/2 NCT07183384 Jul 2024 → Jul 2026 overdue endotheliitis, preeclampsia, puerperal disorder Padjadjaran University Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT07312656 Jan 2026 → Jun 2027 expected mucositis First Affiliated Hospital of Guangxi Medical University Not yet recruiting No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Mesenchymal Stem Cell-Derived Exosomes ClinicalTrials.gov intervention name — accepted as the source's own label NCT07183384 ↗
1

NCT07312656 ↗
Modality Other / unclassified “a new treatment called exosomes” NCT07183384 ↗
Route Intramuscular “administered as a single Intravenous or Intramuscular infusion.” NCT07183384 ↗
Route Intravenous “administered as a single Intravenous or Intramuscular infusion.” NCT07183384 ↗